The Phar-East conference held in March 2019 is a leading pharma and biotech conference for Asia.
Being an industry conference, it was interesting to be invited back again to participate in a panel
discussion, and this time to also present on the opportunities and challenges of a stakeholder
engagement journey from a patient advocate perspective.
I spent the large part of the conference attending various talks on immunotherapy, clinical trials,
pharma 4.0, market access and pricing, regulatory affairs; and one topic which I attended for the first
is around biotech investments.
Here are some of my impressions: